rdf-syntax-grammar
mods: Norway's pharmaceutical revolution pursuing and accomplishing innovation in Nyegaard & Co., 1945-1997 Sogner, Knut creator author. text bibliography Electronic books. History enk 2022 2022 monographic eng remote 1 online resource "The academic–business effort of a handful of primarily large nations—the United States, Germany, Great Britain, Switzerland, and France—culminated in the 1930s and 1940s in a number of potent new therapeutics that created, with subsequent new products over the next decades, what is known as “the pharmaceutical revolution.” This was to a great degree based on academic–business collaboration and proved difficult to accomplish for other large nations like Japan, China, India, Italy, Spain, and Russia, not to mention smaller nations. However, companies in the smaller Scandinavian countries were able to join the group of pioneering nations in a narrow band of products and become original contributors to the pharmaceutical revolution. This book highlights the particular difficulties of the Norwegian experience that counted one major breakthrough and which shows just how challenging it was to join the elite countries in pharmaceuticals. The small and traditional generics company Nyegaard & Co. succeeded only in 1969 with the breakthrough of a new principle for X-ray contrast media. Until the 1960s, it had been distracted and hindered by the national drugs policy. The research success can largely be attributed to corporate competence and corporate initiatives to exploit the Scandinavian rather than the Norwegian medical ecosystem. And the subsequent innovations were made commercial successes through the building of international partnerships with larger corporations. Success came at a price, though, for at the very time the commercial success was at its greatest, in the 1990s, the organization had lost its innovative claw"--Publisher's description. Knut Sogner. Includes bibliographical references and index. e-no--- Nyegaard & Co. History 20th cent…